This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
342
Oral
Oral
Proportion of participants achieving IGA score 0/1 and ≥ 2-step reduction from baseline at Week 24
Time frame: Week 24
Change from baseline in LPP symptom numerical rating scale scores at Week 24
Time frame: Week 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Clinical Trial Site
Birmingham, Alabama, United States
RECRUITINGClinical Trial Site
Phoenix, Arizona, United States
RECRUITINGClinical Trial Site
Scottsdale, Arizona, United States
RECRUITINGClinical Trial Site
Irvine, California, United States
RECRUITINGClinical Trial Site
Oakland, California, United States
RECRUITINGClinical Trial Site
Sacramento, California, United States
RECRUITINGClinical Trial Site
San Francisco, California, United States
RECRUITINGClinical Trial Site
Denver, Colorado, United States
RECRUITINGClinical Trial Site
Farmington, Connecticut, United States
RECRUITINGClinical Trial Site
New Haven, Connecticut, United States
RECRUITING...and 51 more locations